## Mathew L Thakur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8334252/publications.pdf

Version: 2024-02-01

187 5,584 40
papers citations h-index

191 191 191 3517 all docs docs citations times ranked citing authors

67

g-index

#	Article	IF	CITATIONS
1	Indium-111 labeled platelets: Studies on preparation and evaluation of in vitro and in vivo functions. Thrombosis Research, 1976, 9, 345-357.	0.8	465
2	Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. Journal of Nuclear Medicine, 1976, 17, 480-7.	2.8	223
3	Indium-111-labeled autologous leukocytes in man. Journal of Nuclear Medicine, 1977, 18, 1014-21.	2.8	193
4	Sentinel Lymph Nodes in a Swine Model with Melanoma: Contrast-enhanced Lymphatic US. Radiology, 2004, 230, 727-734.	3.6	165
5	Decorin Protein Core Inhibits in Vivo Cancer Growth and Metabolism by Hindering Epidermal Growth Factor Receptor Function and Triggering Apoptosis via Caspase-3 Activation. Journal of Biological Chemistry, 2006, 281, 26408-26418.	1.6	157
6	An Antimetastatic Role for Decorin in Breast Cancer. American Journal of Pathology, 2008, 173, 844-855.	1.9	136
7	Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. Translational Research, 1977, 89, 217-28.	2.4	131
8	INDIUM-111-LABELLED LEUCOCYTES FOR LOCALISATION OF ABSCESSES. Lancet, The, 1976, 308, 1056-1058.	6.3	125
9	VEGF Trap in Combination With Radiotherapy Improves Tumor Control in U87 Glioblastoma. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1526-1537.	0.4	123
10	Endorepellin In Vivo: Targeting the Tumor Vasculature and Retarding Cancer Growth and Metabolism. Journal of the National Cancer Institute, 2006, 98, 1634-1646.	3.0	106
11	Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Applied Radiation and Isotopes, 2002, 57, 749-763.	0.7	98
12	Indium-111-labeled human platelets: improved method, efficacy, and evaluation. Journal of Nuclear Medicine, 1981, 22, 381-5.	2.8	89
13	Radiolabeled Peptides in Oncology. BioDrugs, 2005, 19, 145-163.	2.2	87
14	Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. Journal of Nuclear Medicine, 1977, 18, 1022-6.	2.8	85
15	Kinetics of indium-III labelled lymphocytes in normal subjects and patients with Hodgkin's disease BMJ: British Medical Journal, 1977, 2, 797-799.	2.4	83
16	Preparation and Evaluation of $\frac{11}{\text{sup}}$ In-Labeled Leukocytes as an Abscess Imaging Agent in Dogs. Radiology, 1976, 119, 731-732.	3.6	80
17	Gallium-67 and indium-111 radiopharmaceuticals. The International Journal of Applied Radiation and Isotopes, 1977, 28, 183-201.	0.7	73
18	Indium-111-labeled human polymorphonuclear leukocytes: viability, random migration, chemotaxis, bacterial capacity, and ultrastructure. Journal of Nuclear Medicine, 1979, 20, 741-7.	2.8	69

#	Article	IF	CITATIONS
19	Molecular Determinants of Epidermal Growth Factor Binding: A Molecular Dynamics Study. PLoS ONE, 2013, 8, e54136.	1.1	61
20	Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. II. Particles. Journal of Nuclear Medicine, 1976, 17, 488-92.	2.8	61
21	Report of a Summit on Molecular Imaging. Radiology, 2005, 236, 753-755.	3.6	60
22	Recent Trends in Soft-Tissue Infection Imaging. Seminars in Nuclear Medicine, 2009, 39, 115-123.	2.5	60
23	Lactoferrin: its role as a Ga-67-binding protein in polymorphonuclear leukocytes. Journal of Nuclear Medicine, 1981, 22, 32-7.	2.8	59
24	CCR5 Receptor Antagonists Block Metastasis to Bone of v-Src Oncogene–Transformed Metastatic Prostate Cancer Cell Lines. Cancer Research, 2014, 74, 7103-7114.	0.4	58
25	Radiolabeled somatostatin analogs in prostate cancer. Nuclear Medicine and Biology, 1997, 24, 105-113.	0.3	57
26	Imaging experimental infective endocarditis with indium-111-labeled blood cellular components Circulation, 1979, 59, 336-343.	1.6	53
27	An experimental comparison of radioactive labels with potential application to lymphocyte migration studies in patients. Clinical and Experimental Immunology, 1977, 29, 509-14.	1.1	53
28	Imaging experimental coronary artery thrombosis with indium-111 platelets Circulation, 1979, 60, 767-775.	1.6	52
29	99mTc-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. Journal of Nuclear Medicine, 2000, 41, 107-10.	2.8	51
30	Radiolabeled peptides in diagnosis and therapy. Seminars in Nuclear Medicine, 2001, 31, 296-311.	2.5	49
31	PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. Journal of Nuclear Medicine, 2004, 45, 1381-9.	2.8	49
32	Imaging experimental myocardial infarction with indium-111-labeled autologous leukocytes: effects of infarct age and residual regional myocardial blood flow Circulation, 1979, 60, 297-305.	1.6	48
33	Guanylyl Cyclase C–Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity. Journal of the National Cancer Institute, 2008, 100, 950-961.	3.0	48
34	PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. Journal of Nuclear Medicine, 2008, 49, 112-121.	2.8	46
35	Gallium-68 labeled red cells and platelets: new agents for positron tomography. Journal of Nuclear Medicine, 1977, 18, 558-62.	2.8	45
36	99mTc-labeled vasoactive intestinal peptide receptor agonist: functional studies. Journal of Nuclear Medicine, 1999, 40, 352-60.	2.8	44

#	Article	IF	CITATIONS
37	External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. Journal of Nuclear Medicine, 2004, 45, 2070-82.	2.8	43
38	Radiohybridization PET imaging of KRAS G12D mRNA expression in human pancreas cancer xenografts with [64Cu]DO3A-peptide nucleic acid-peptide nanoparticles. Cancer Biology and Therapy, 2007, 6, 948-956.	1.5	42
39	Radiolabelled peptides. Nuclear Medicine Communications, 1995, 16, 724-732.	0.5	41
40	External Imaging of CCND1, MYC, and KRASOncogene mRNAs with Tumor-Targeted Radionuclide-PNA-Peptide Chimeras. Annals of the New York Academy of Sciences, 2005, 1059, 106-144.	1.8	41
41	Noninvasive Molecular Imaging of MYC mRNA Expression in Human Breast Cancer Xenografts with a [99mTc]Peptideâ^'Peptide Nucleic Acidâ^'Peptide Chimera. Bioconjugate Chemistry, 2005, 16, 70-79.	1.8	41
42	PET Imaging of CCND1 mRNA in Human MCF7 Estrogen Receptor Positive Breast Cancer Xenografts with Oncogene-Specific [64Cu]Chelator-Peptide Nucleic Acid-IGF1 Analog Radiohybridization Probes. Journal of Nuclear Medicine, 2007, 48, 1699-1707.	2.8	41
43	Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3. Nuclear Medicine Communications, 1994, 15, 824-830???830.	0.5	40
44	Radiopharmaceuticals for spleen and bone marrow studies. Seminars in Nuclear Medicine, 1985, 15, 229-238.	2.5	39
45	Technetium-99m stannous pyrophosphate imaging of experimental infective endocarditis Circulation, 1978, 58, 111-119.	1.6	38
46	99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nuclear Medicine and Biology, 2001, 28, 445-450.	0.3	37
47	Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regulatory Peptides, 2007, 144, 91-100.	1.9	37
48	The significance of chromosomal aberrations in indium-111-labeled lymphocytes. Journal of Nuclear Medicine, 1984, 25, 922-7.	2.8	37
49	Imaging vascular thrombosis with 99mTc-labeled fibrin alpha-chain peptide. Journal of Nuclear Medicine, 2000, 41, 161-8.	2.8	36
50	Technetium-99m-labeled monoclonal antibodies for immunoscintigraphy. Journal of Immunological Methods, 1991, 137, 217-224.	0.6	35
51	Neutrophil labeling: Problems and pitfalls. Seminars in Nuclear Medicine, 1984, 14, 107-117.	2.5	34
52	Synthesis, In Vitro Binding, and Tissue Distribution of Radioiodinated 2-[125I]N-(N-Benzylpiperidin-4-yl)-2-lodo Benzamide, 2-[125I]BP: A Potential Ïf Receptor Marker for Human Prostate Tumors. Nuclear Medicine and Biology, 1998, 25, 189-194.	0.3	34
53	Currently Available Radiopharmaceuticals for Imaging Infection and the Holy Grail. Seminars in Nuclear Medicine, 2018, 48, 86-99.	2.5	33
54	Fluorescence Detection of <i>KRAS2</i> mRNA Hybridization in Lung Cancer Cells with PNA-Peptides Containing an Internal Thiazole Orange. Bioconjugate Chemistry, 2014, 25, 1697-1708.	1.8	32

#	Article	IF	CITATIONS
55	The preparation of iodine-123 labelled sodium ortho-iodo hippurate and its clearance by the rat kidneys. The International Journal of Applied Radiation and Isotopes, 1975, 26, 319-320.	0.7	30
56	Imaging of the inflammatory response in ischemic canine myocardium with 111indium-labeled leukocytes. American Journal of Cardiology, 1977, 40, 195-199.	0.7	30
57	Imaging Human Pancreatic Cancer Xenografts by Targeting Mutant <i>KRAS2</i> mRNA with [ <sup>111</sup> In]DOTA <sub><i>n</i> Cys-Ser-Lys-Cys) Nanoparticles. Bioconjugate Chemistry, 2010, 21, 731-740.</sub>	1.8	30
58	Imaging inflammatory diseases with neutrophil-specific technetium-99m-labeled monoclonal antibody anti-SSEA-1. Journal of Nuclear Medicine, 1996, 37, 1789-95.	2.8	30
59	The preparation of Indium-111 labelled bleomycin for tumour localisation. The International Journal of Applied Radiation and Isotopes, 1973, 24, 357-359.	0.7	29
60	VPAC1 Receptors for Imaging Breast Cancer: A Feasibility Study. Journal of Nuclear Medicine, 2013, 54, 1019-1025.	2.8	29
61	Imaging Tumors in Humans with Tcâ€99mâ€VIP. Annals of the New York Academy of Sciences, 2000, 921, 37-44.	1.8	28
62	99mTc-peptide-peptide nucleic acid probes for imaging oncogene mRNAs in tumours. Nuclear Medicine Communications, 2003, 24, 857-863.	0.5	27
63	Imaging thromboembolism with fibrin-avid 99mTc-peptide: evaluation in swine. Journal of Nuclear Medicine, 2006, 47, 155-62.	2.8	27
64	Cyclotron production of carrier-free Gallium-67. The International Journal of Applied Radiation and Isotopes, 1970, 21, 630-631.	0.7	26
65	Cyclotron produced indium-111 for medical use. The International Journal of Applied Radiation and Isotopes, 1972, 23, 139-140.	0.7	26
66	Neutrophil-specific 99mTc-labeled anti-CD15 monoclonal antibody imaging for diagnosis of equivocal appendicitis. Journal of Nuclear Medicine, 2000, 41, 449-55.	2.8	26
67	Cyclotron isotopes and radiopharmaceuticals—XXX. Aspects of production, elution and automation of 81Rbî—,81Kr generators. The International Journal of Applied Radiation and Isotopes, 1980, 31, 51-59.	0.7	25
68	Effects of Hypoxanthine Substitution in Peptide Nucleic Acids Targeting <i>KRAS2</i> Oncogenic mRNA Molecules: Theory and Experiment. Journal of Physical Chemistry B, 2013, 117, 11584-11595.	1.2	25
69	Monoclonal antibodies as agents for selective radiolabeling of human neutrophils. Journal of Nuclear Medicine, 1988, 29, 1817-25.	2.8	25
70	Studies with radioactive iodine labelled oestrogens as prostate scanning agents. The International Journal of Applied Radiation and Isotopes, 1975, 26, 343-346.	0.7	24
71	Imaging infection with LeuTech®. Nuclear Medicine Communications, 2001, 22, 513-519.	0.5	24
72	Murine <i> <scp>MPDZ</scp> </i> â€linked hydrocephalus is caused by hyperpermeability of the choroid plexus. EMBO Molecular Medicine, 2019, 11, .	3.3	24

#	Article	IF	CITATIONS
73	Radionuclides: Applications in Diagnostic and Therapeutic Nuclear Medicine. Radiochimica Acta, 1995, 70-71, 273-288.	0.5	24
74	Report of a Summit on Molecular Imaging. American Journal of Roentgenology, 2006, 186, 297-299.	1.0	23
75	Genomic Biomarkers for Molecular Imaging: Predicting the Future. Seminars in Nuclear Medicine, 2009, 39, 236-246.	2.5	23
76	Physiologically Based Pharmacokinetics of Molecular Imaging Nanoparticles for mRNA Detection Determined in Tumor-Bearing Mice. Oligonucleotides, 2010, 20, 117-125.	2.7	23
77	A simplified method of selective spleen scintigraphy with Tc-99m-labeled erythrocytes: clinical applications. Concise communication. Journal of Nuclear Medicine, 1980, 21, 413-6.	2.8	23
78	Imaging the inflammatory response to acute myocardial infarction in man using indium-111-labeled autologous platelets Circulation, 1981, 63, 826-832.	1.6	22
79	VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. Urology, 2016, 88, 111-118.	0.5	21
80	Simplified and efficient labeling of human platelets in plasma using indium-111-2-mercaptopyridine-N-oxide: preparation and evaluation. Journal of Nuclear Medicine, 1985, 26, 510-7.	2.8	21
81	Desferoxamine Mesylate (Desferal): A Contrast-Enhancing Agent for Gallium-67 Imaging. Radiology, 1979, 131, 775-779.	3.6	20
82	A Simple Method of Spleen Imaging with < sup > 99m < /sup > Tc-Labeled Erythrocytes. Radiology, 1979, 132, 215-216.	3.6	20
83	Imaging Thromboembolism with Tc-99m–Labeled Thrombospondin Receptor Analogs TP-1201 and TP-1300. Thrombosis Research, 1999, 93, 191-202.	0.8	20
84	Indium-111-labeled human platelets: uptake and loss of label and in vitro function of labeled platelets. Translational Research, 1978, 92, 829-36.	2.4	20
85	Rhenium-labeled somatostatin analog RC-160. 1H NMR and computer modeling conformational analysis. Journal of Biological Chemistry, 1994, 269, 12583-8.	1.6	20
86	Technetium-99m labeled monoclonal antibodies: Evaluation of reducing agents. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 227-233.	0.3	19
87	SYNTHESIS OF NOVEL PEPTIDE NUCLEIC ACID-PEPTIDE CHIMERA FOR NON-INVASIVE IMAGING OF CANCER. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 409-414.	0.4	19
88	Fluorescent Peptide–PNA Chimeras for Imaging Monoamine Oxidase A mRNA in Neuronal Cells. Bioconjugate Chemistry, 2012, 23, 158-163.	1.8	19
89	Targeting Apoptosis for Optical Imaging of Infection. Molecular Imaging and Biology, 2012, 14, 163-171.	1.3	19
90	Cell labeling: achievements, challenges, and prospects. Journal of Nuclear Medicine, 1981, 22, 1011-4.	2.8	19

#	Article	IF	CITATIONS
91	1982 GEORGE SIMON MEMORIAL FELLOWSHIP AWARD Experimental Studies with 111Indium-Labeled Platelets in Pulmonary Embolism. Investigative Radiology, 1982, 17, 367-373.	3.5	18
92	A receptor-specific peptide for imaging infection and inflammation. Nuclear Medicine Communications, 2000, 21, 1063-1070.	0.5	18
93	Design of (Gdâ€DO3A) <sub><i>n</i></sub> â€polydiamidopropanoylâ€peptide nucleic acidâ€ <scp>D</scp> (Cysâ€Serâ€Lysâ€Cys) magnetic resonance contrast agents. Biopolymers, 2008, 89, 1061-10	o <del>76</del> .	18
94	Imaging Spontaneous MMTVneu Transgenic Murine Mammary Tumors: Targeting Metabolic Activity Versus Genetic Products. Journal of Nuclear Medicine, 2010, 51, 106-111.	2.8	18
95	<sup>111</sup> In-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen. British Journal of Radiology, 1975, 48, 279-285.	1.0	17
96	Cyclotron produced lead-203. Postgraduate Medical Journal, 1975, 51, 751-754.	0.9	17
97	Evaluation of a method for the preparation of high specific activity radioionated oestradiol. The International Journal of Applied Radiation and Isotopes, 1976, 27, 585-588.	0.7	17
98	Imaging Oncogene Expression. Annals of the New York Academy of Sciences, 2003, 1002, 165-188.	1.8	17
99	Receptor-mediated internalization of chelator–PNA–peptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochemical Society Transactions, 2007, 35, 72-76.	1.6	17
100	The production of potassium-43 for medical use. The International Journal of Applied Radiation and Isotopes, 1972, 23, 329-330.	0.7	15
101	Imaging oncogene expression. European Journal of Radiology, 2009, 70, 265-273.	1.2	15
102	Radioisotopic Labeling of Platelets: A Historical Perspective. Seminars in Thrombosis and Hemostasis, 1983, 9, 79-85.	1.5	14
103	MR imaging of pulmonary parenchyma and emboli by paramagnetic and superparamagnetic contrast agents. Magnetic Resonance Imaging, 1990, 8, 625-630.	1.0	14
104	The influence of ligand on the tissue distribution of carrier free 111In in the rat. International Journal of Nuclear Medicine and Biology, 1975, 2, 45-48.	0.7	13
105	Evaluation of biological response modifiers in the enhancement of tumor uptake of technetium-99m labeled macromolecules. Journal of Immunological Methods, 1992, 152, 209-216.	0.6	13
106	PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma. Nuclear Medicine Communications, 2011, 32, 563-569.	0.5	13
107	Determination of reduced disulfide groups in monoclonal antibodies. BioTechniques, 1990, 8, 512-6.	0.8	13
108	The preparation of iodine-123 labelled contrast agents. The International Journal of Applied Radiation and Isotopes, 1974, 25, 576-578.	0.7	12

#	Article	IF	CITATIONS
109	Detection of pulmonary embolism in man with 111In-labeled autologous platelets. American Journal of Roentgenology, 1982, 138, 945-947.	1.0	12
110	Immunoscintigraphic imaging of inflammatory lesions: Preliminary findings and future possibilities. Seminars in Nuclear Medicine, 1990, 20, 92-98.	2.5	12
111	Labelling of platelets with indium-111 oxine and technetium-99m hexamethylpropylene amine oxime: suggested methods. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1614-1616.	3.3	12
112	TUMOR-TARGETING PEPTIDE-PNA-PEPTIDE CHIMERAS FOR IMAGING OVEREXPRESSED ONCOGENE mRNAS. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1085-1091.	0.4	12
113	In vivo investigation of the tissue response to commercial Teflon insulin infusion sets in large swine for 14 days: the effect of angle of insertion on tissue histology and insulin spread within the subcutaneous tissue. BMJ Open Diabetes Research and Care, 2019, 7, e000881.	1.2	12
114	Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites. Journal of Nuclear Medicine, 1994, 35, 876-81.	2.8	12
115	Preparation and evaluation of [99mTc]DEPE as a cardiac perfusion agent. The International Journal of Applied Radiation and Isotopes, 1984, 35, 507-515.	0.7	11
116	Radionuclides: Applications in Diagnostic and Therapeutic Nuclear Medicine. Radiochimica Acta, 1995, 70-71, 273-288.	0.5	11
117	Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA. Nuclear Medicine and Biology, 2013, 40, 994-999.	0.3	11
118	A glance at imaging bladder cancer. Clinical and Translational Imaging, 2018, 6, 257-269.	1.1	11
119	Evaluating Ga-68 Peptide Conjugates for Targeting VPAC Receptors: Stability and Pharmacokinetics. Molecular Imaging and Biology, 2019, 21, 130-139.	1.3	11
120	Evaluation of indium-111-2-mercaptopyridine-N-oxide for labeling leukocytes in plasma: a kit preparation. Journal of Nuclear Medicine, 1985, 26, 518-23.	2.8	11
121	Radiolabeled Blood Cells: Techniques and Applications. CRC Critical Reviews in Clinical Laboratory Sciences, 1986, 24, 95-122.	1.0	10
122	99mTc-Fanolesomab: affinity, pharmacokinetics and preliminary evaluation. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2006, 50, 104-12.	0.4	10
123	Transient neutropenia: neutrophil distribution and replacement. Journal of Nuclear Medicine, 1996, 37, 489-94.	2.8	9
124	Apoptotic abscess imaging with 99mTc-HYNIC-rh-Annexin-V. Nuclear Medicine and Biology, 2010, 37, 29-34.	0.3	8
125	Effects of a 99mTc-labeled murine immunoglobulin M antibody to CD15 antigens on human granulocyte membranes in healthy volunteers. Journal of Nuclear Medicine, 1999, 40, 2107-14.	2.8	8
126	Role of lipid-soluble complexes in targeted tumor therapy. Journal of Nuclear Medicine, 2003, 44, 1293-300.	2.8	8

#	Article	IF	CITATIONS
127	Monoclonal antibodies for specific cell labeling: Considerations, preparations and preliminary evaluation. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1987, 14, 51-58.	0.3	7
128	Augmenting of tumor uptake of anti-melanoma antibody MEM136: Influence of interferon. Nuclear Medicine and Biology, 1996, 23, 873-879.	0.3	7
129	Comparison of leukocytes labeled with indium-111-2-mercaptopyridine-N-oxide and indium-111 oxine for abscess detection. Journal of Nuclear Medicine, 1987, 28, 438-41.	2.8	7
130	Chemistry of Gallium and Indium Radiopharmaceuticals., 2005,, 363-399.		6
131	Development of a voided urine assay for detecting prostate cancer nonâ€invasively: a pilot study. BJU International, 2017, 119, 885-895.	1.3	6
132	Technetium-99m-labeled proteins for imaging inflammatory foci. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1991, 18, 605-612.	0.3	5
133	Evaluation of a PACAP Peptide Analogue Labeled with <sup>68</sup> Ga Using Two Different Chelating Agents. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 29-36.	0.7	5
134	VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. World Journal of Urology, 2018, 36, 719-726.	1.2	5
135	Effect of antiarrhythmic drugs on In-111-labeled leukocytes: chemotaxis and adherence to nylon wool. Journal of Nuclear Medicine, 1982, 23, 131-5.	2.8	5
136	The Production of 117Sb-labelled potassium antimonyl tartrate for medical use. The International Journal of Applied Radiation and Isotopes, 1970, 21, 33-36.	0.7	4
137	Determination of microgram quantities of gadolinium by cathode-ray polarography. Talanta, 1974, 21, 771-775.	2.9	4
138	Preparation, characterization and evaluation of DMPE as a myocardial imaging agent. The International Journal of Applied Radiation and Isotopes, 1983, 34, 617-624.	0.7	4
139	Human neutrophils. Nuclear Medicine Communications, 1990, 11, 37-44.	0.5	4
140	Use of ferrum in MRI of lung parenchyma and pulmonary embolism. Magnetic Resonance Imaging, 1993, 11, 499-508.	1.0	4
141	Influence of Biological Response Modifiers. Journal of Immunotherapy, 1994, 16, 175-180.	1.2	4
142	Effect of interferon-α-2b on the enhancement of tumour uptake of 99Tcm-labelled monoclonal antibodies. Nuclear Medicine Communications, 1996, 17, 346-352.	0.5	4
143	VPAC1 Targeted 64 Cu-TP3805 kit preparation and its evaluation. Nuclear Medicine and Biology, 2017, 51, 55-61.	0.3	4
144	Targeting VPAC1 Receptors for Imaging Glioblastoma. Molecular Imaging and Biology, 2020, 22, 293-302.	1.3	4

#	Article	IF	Citations
145	Live bacteria labeled with 111In. European Journal of Nuclear Medicine and Molecular Imaging, 1987, 13, 266.	2.2	3
146	Radiation dosimetry of a 99mTc-labeled IgM murine antibody to CD15 antigens on human granulocytes. Journal of Nuclear Medicine, 1999, 40, 625-30.	2.8	3
147	The Influence of Heparin on the In Vivo Distribution of IN-111 Labeled Platelets. Investigative Radiology, 1985, 20, 198-202.	3.5	2
148	Artifactual Focal Lung Activity with Indium-111 Labeled Leukocytes. Clinical Nuclear Medicine, 1986, 11, 840-841.	0.7	2
149	Distribution of Iodized Oil within the Liver after Hepatic Arterial Injection. Radiology, 1987, 164, 585-586.	3.6	2
150	Improved Antibody Targeting with Interferon-??-2b Conjugate. Journal of Immunotherapy, 1997, 20, 194-195.	1.2	2
151	Fibrin avid <sup>99m</sup> TCâ€peptide for imaging thrombosis. Journal of Labelled Compounds and Radiopharmaceuticals, 2001, 44, S48.	0.5	2
152	Oncogene mRNA imaging with 99mTc-chelator-PNA-peptides. Russian Chemical Bulletin, 2002, 51, 1083-1099.	0.4	2
153	Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy. Current Molecular Imaging, 2012, 1, 3-11.	0.7	2
154	RADIOLABELED BLOOD CELLS: AGENTS FOR DIAGNOSTIC AND KINETIC STUDIES. , 1982, , 115-125.		2
155	Radiolabelled peptides: now and the future. Nuclear Medicine Communications, 1995, 16, 724-32.	0.5	2
156	Analytical control of a radiopharmaceutical using a cathode ray polarograph. Journal of Radioanalytical Chemistry, 1975, 24, 89-97.	0.5	1
157	A look at radiolabeled blood cells. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1986, 13, 147-158.	0.3	1
158	Ultrastructure of human platelets following indium-111 labeling in plasma. Nuclear Medicine Communications, 1987, 8, 69-78.	0.5	1
159	Platelet Sequestration in Widespread Pulmonary Hemangiolymphangiectasia Demonstration by Indium-111 Labeled Platelets. Clinical Nuclear Medicine, 1987, 12, 215-216.	0.7	1
160	Radioiodinated rhodamine-123: Preparationand preliminary evaluation as an agent for tumor scintigraphy. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1988, 15, 517-524.	0.3	1
161	Radiolabeled blood cells: Perspectives and directions. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 41-47.	0.3	1
162	Solid phase preparations of 99mTc labeled radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals, 2002, 45, 231-239.	0.5	1

#	Article	IF	Citations
163	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2003, 10, 191-214.	0.9	1
164	Radionuclide–Peptide Nucleic Acid in Diagnosis and Treatment of Pancreatic Cancer. , 2005, 106, 135-192.		1
165	Simulation of a pinhole-collimator insert for small animal PET using GATE., 2007,,.		1
166	Receptor-Specific Targeting with Complementary Peptide Nucleic Acids Conjugated to Peptide Analogs and Radionuclides. , 2006, , 61-88.		1
167	Genetic and Molecular Approaches to Imaging Breast Cancer. , 2010, , 163-182.		1
168	Potential of Radiolabeled Antiplatelet Antibodies in the Detection of Vascular Thrombi., 1988,, 831-845.		1
169	Consistent Surgeon Evaluations of Three-Dimensional Rendering of PET/CT Scans of the Abdomen of a Patient with a Ductal Pancreatic Mass. PLoS ONE, 2013, 8, e75237.	1.1	1
170	Techniques of Cell Labeling: An Overview. , 1985, , 67-87.		1
171	Human neutrophils: evaluation of adherence, chemotaxis and phagocytosis, following interaction with radiolabeled antibodies. Nuclear Medicine Communications, 1990, 11, 37-43.	0.5	1
172	New radionuclides in the diagnosis of obscure infections. Connecticut Medicine, 1981, 45, 302-4.	0.2	1
173	Three dimensional projection environment for molecular design and surgical simulation. Studies in Health Technology and Informatics, 2011, 163, 691-5.	0.2	1
174	Discordant Gallium???67 and Indium???111 Leukocyte Images in a Suspected Pelvic Abscess. Clinical Nuclear Medicine, 1984, 9, 654.	0.7	0
175	Preparation and evaluation of new bifunctional chelating agents: a preliminary report. International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology, 1990, 17, 181-188.	0.3	0
176	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2003, 10, 191-214.	0.1	0
177	Oncogene mRNA Imaging with99mTc-Chelator-PNA-Peptides ChemInform, 2003, 34, no.	0.1	0
178	Receptor-specific targeting with complementary peptide nucleic acids conjugated to peptide analogs and radionuclides. International Journal of Peptide Research and Therapeutics, 2005, 10, 191-214.	0.9	0
179	John McAfee, MD (1926–2008), In Memoriam. Nuclear Medicine and Biology, 2009, 36, 343-344.	0.3	0
180	Radiolabeled biomolecules for specific imaging of cancers of the breast, prostate and lungs. Journal of Radioanalytical and Nuclear Chemistry, 2014, 302, 857-867.	0.7	0

#	Article	lF	CITATIONS
181	Advanced approaches to imaging primary breast cancer: an update. Clinical and Translational Imaging, 2019, 7, 381-404.	1.1	O
182	SPECT Radiochemistry., 2021,, 479-492.		0
183	The Use of Radiolabeled Monoclonal Antibodies in Inflammatory Bowel Diseases., 2003,, 40-46.		0
184	Peptides and Proteins in Radiolabeling of Blood Elements. , 1994, , 187-194.		0
185	Targeting Tumors with Iodine-123 Labeled Deoxyuridine: Distribution and DNA Binding. Cancer Detection and Prevention, 1999, 23, 72-77.	2.1	0
186	Imaging cancer gene activity in patients from outside the body. Biotechnology Healthcare, 2006, 3, 45-8.	0.2	0
187	Imaging urothelial bladder cancer: A VPAC PET targeted approach. Canadian Journal of Urology, 2021, 28, 10596-10602.	0.0	0